Laser assisted periodontium and osseus regeneration protocol
A method of treating gum disease using a soft tissue diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400 nm-700 nm) at a laser power of 0.5 to 1.2 watts, used with intermittent stops to control tissue temperature, to decontaminate the gum tissue and biostimulate the periodontium nonsurgically when used with a substrate, thus preventing the long junctional epithelium from migrating into the sulcus, preserving tissue height, and regenerating periodontium, the method comprising: placing the tip of the laser inside the sulcus; penetrating the entire sulcus by moving the laser light with intermittent stops to control tissue temperature vertically and horizontally throughout the sulcus; and placing a substrate in the sulcus prior to a blood clot forming, thus regenerating periodontium in the sulcus.
1. A substrate mixture for the treatment of gum disease, wherein the substrate mixture is comprised of:
a) a first substrate; and
b) a second substrate,
wherein the first substrate is comprised of:
a) between 40% and 80% sterile water
b) 1.1% sodium chloride;
c) 1% benzoic acid;
d) 9% lysine;
e) 9% proline;
f) 9% essential amino acids, wherein the essential amino acids include equal parts isoleucine, leucine, methionine, phenylalanine, threonine, tryptophan, valine and histadine;
g) 2% non-essential amino acids, wherein the non-essential amino acids include equal parts alanine, arginine, glutamate, glycine and serine;
h) 2% phosphates, wherein the phosphates include equal parts adenosine diphospate (ADP), adenosine triphosphate (ATP), and acetylcholine; and
i) 6.9% free bases, wherein the free bases include equal parts adenosine, uridine, guanosine, and cytidine.
2. The substrate mixture of claim 1 , wherein the second substrate is comprised of:
a) tricalcium phosphate; and
b) hydroxyapatite crystals.
3. The substrate mixture of claim 1 , wherein the first substrate includes aspartate in an equal amount relative to the other non-essential amino acids.
4. The substrate mixture of claim 1 , wherein the first substrate includes aspartate in a greater amount relative to the other non-essential amino acids.
5. The substrate mixture of claim 1 , wherein the substrate mixture has a pH of about 7.4.
6. The substrate mixture of claim 2 , wherein the tricalcium phosphate is precipitated in calcium hydroxide and devil's claw oil.
7. The substrate mixture of claim 2 , wherein the hydroxyapatite crystals are precipitated in calcium hydroxide and devil's claw oil.
8. The substrate mixture of claim 2 , wherein the tricalcium phosphate is in the form of crystals.
9. The substrate mixture of claim 8 , wherein the tricalcium phosphate crystals are 10-50 micro meter in size.
10. The substrate mixture of claim 8 , wherein the tricalcium phosphate crystals are 50-150 micro meter in size.
11. The substrate mixture of claim 8 , wherein the tricalcium phosphate crystals are 100-300 micro meter in size.
12. The substrate mixture of claim 8 , wherein the tricalcium phosphate crystals are 500-1000 micro meter in size.
13. The substrate mixture of claim 8 , wherein the tricalcium phosphate crystals are 1-3 mm in size.
14. The substrate mixture of claim 2 , wherein the hydroxyapatite crystals are non-porous.
15. The substrate mixture of claim 2 , wherein the hydroxyapatite crystals are porous.
16. The substrate mixture of claim 8 , wherein the tricalcium phosphate crystals are non-porous.
17. The substrate mixture of claim 8 , wherein the tricalcium phosphate crystals are porous.